Nov 17, 2026 ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline
Nov 12, 2026 ProMIS Neurosciences Announces Third Quarter 2026 Financial Results and Reaffirms First Quarter 2027 Topline Data Timing
Nov 3, 2026 ProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026
Oct 6, 2026 ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer
Aug 13, 2026 ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
Aug 3, 2026 ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
Jul 28, 2026 ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial